☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Immuneering Corporation
Immuneering Reports First Patient Dosing with IMM-6-415 in the P-I/IIa Study for Treating Advanced Solid Tumors
March 28, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.